European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- May 2026

The European Pharmacopoeia (Ph. Eur.) Monograph 0478, (Compressi), defines the general quality, manufacturing, and testing standards for tablet preparations, including requirements for dissolution and mass uniformity. It specifies standards for various types, such as uncoated, coated, and gastro-resistant tablets, often requiring compliance with additional Ph. Eur. chapters. For the full text, see uspbpep.com

While disintegration shows the tablet breaking apart, dissolution measures the rate at which the active substance enters solution. Under recent policies, a suitable product-specific dissolution test is mandatory for most immediate-release solid dosage forms to confirm batch-to-batch consistency. 3. Uniformity of Dosage Units (General Chapter 2.9.40) European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

• Elegantly links to other Ph. Eur. chapters (e.g., 2.9.40 for uniformity of dosage units, 5.15 for functional coatings). This avoids redundancy and ensures consistency across monographs.

According to the Ph. Eur. monograph for Tablets - 0478, tablets are defined as solid dosage forms that contain one or more active pharmaceutical ingredients (APIs) compressed into a single dose. The composition of tablets may vary, but they typically consist of: The European Pharmacopoeia (Ph

Night fell and the lab emptied, but Elena stayed to draft the suggested revisions. Her edits were precise: revised procedural steps, justification notes, and a proposed transitional timeline. She added a short explanatory paragraph to the monograph’s commentary section — not normative, but instructive — describing best practices for handling hygroscopic tablets. It was a small act of stewardship: improving clarity where ambiguity caused unnecessary burden. Elegantly links to other Ph

• Mandates Uniformity of Mass (2.9.5) or Uniformity of Content (2.9.6) depending on the active substance content. This is critical for dose consistency.

• Name and strength of each active substance.
• Batch number and expiry date.
• Special storage instructions.
• For sugar-coated tablets: the coating composition need not be declared unless allergenic (e.g., gluten, lactose).

• Use of either content uniformity (individual assay) or weight variation tests depending on tablet API dosage and solubility profile, following the Ph. Eur. general chapters.